Trastuzumab botidotin
As of the edition of 20 October 2026, Trastuzumab botidotin is an antibody drug conjugate: in active development; acts on ERBB2, TUBB and TUBB1 and 7 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody drug conjugate
- Registered trials
- 5, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Ear, nose and throat; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | P04626 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 3 | 1 | 1 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Klus Pharma | Lead sponsor of trials | 2018 to now |
| Sichuan Kelun-Biotech Biopharmaceutical | Lead sponsor of trials | 2018 to now |